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Abstract
The angiotensin II type 1 receptor (AGTR1) plays an integral role in blood pressure control, and is 
implicated in the pathogenesis of hypertension. Polymorphisms within this gene have been 
extensively studied in association with hypertension; however, findings are conflicting. To clarify 
these data, we conducted a systematic review of association studies of AGTR1 polymorphisms and 
hypertension, and performed a meta-analysis of the rs5186 variant. Results show that the currently 
available literature is too heterogeneous to draw meaningful conclusions. The definition of 
hypertension and gender composition of individual studies helps to explain this heterogeneity. 
Although the structure and splicing pattern of AGTR1 would suggest a likely effect of 
polymorphisms within the promoter region on gene function, few studies have been conducted 
thus far. In conclusion, there is insufficient evidence that polymorphisms in the AGTR1 gene are 
risk factors for hypertension. However, most studies are inadequately powered, and larger well-
designed studies of haplotypes are warranted.
BACKGROUND
Gene
The renin-angiotensin system (RAS) plays a fundamental role in blood pressure 
maintenance and is implicated as a likely etiologic factor in the development of 
hypertension.1 Angiotensin II is central to the pathway of the RAS, causing 
vasoconstriction, sodium, and water retention and is tightly intertwined with the cascade of 
inflammatory, thrombotic, and fibrotic factors.1,2 These effects are mediated directly and 
indirectly via two distinct receptors, angiotensin II receptor type 1 (AGTR1) and type 2 
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(AGTR2).2 The bulk of the literature supports AGTR1 as a likely culprit in pathologic states 
such as hypertension. In fact, angiotensin receptor blockers specific to AGTR1 are 
commonly prescribed antihypertensive medications which have also been shown to reduce 
the risk of other cardiovascular endpoints, independent of their antihypertensive effects.3,4 
As such, the AGTR1 is an excellent candidate gene in the etiology of hypertension and other 
cardiovascular diseases (CVD).
The AGTR1 gene is located on chromosome 3q21–25 and is more than 55 Kb long.5,6 Four 
transcription initiation sites have been described.5,7–9 AGTR1 is composed of five exons, 
with the first four encoding the 5′ untranslated region (UTR) and the fifth being the coding 
region.5 Five transcript variants have been reported.5 The abundance of variant 5 is 
negligible and some have discounted the existence of exon 4.7 Exon 3 contains an ATG start 
site that is in-frame with the ATG start site of the open reading frame of exon 5. Hence, 
transcript variant 3 and 4 wherein exon 5 is juxtaposed to exon 5 produces a receptor 
isoform with an additional 32 amino acids at the N-terminus.7 Its presence has been 
substantiated in vivo and seems to result in decreased affinity for angiotensin II.10 The five 
AGTR1 receptor variants also vary with respect to their relative tissue expression, with the 
heart and kidney mostly expressing variants 1 and 2.10
The single promoter in the 5′ region contains multiple regulatory sequences including 
several potential TATA boxes, two CAAT boxes, two overlapping SP1 recognition 
sequences, a GC box, and a cyclic-AMP-induced responsive element.5,9,11 Located in the 3′ 
region are two polyadenylation signals (AATAAA) and six nucleotide motifs in the 3′ 
region which correspond to an AUUUA sequence which may influence mRNA stability 
during posttranscriptional regulation.8 The AGTR1 product is found predominantly in 
vascular smooth muscle cells and the heart, adrenal gland, and kidney.2 The predominant 
short isoform is composed of 359 amino acids and has a molecular mass of 41.1 kDa.8 The 
longer isoform is composed of 391 amino acids and is an additional 3.8 kDa larger.7 It is a 
G-protein coupled receptor spanning seven transmembrane domains.8 The protein sequence 
of the gene product is well conserved.7
Gene variants and frequency
Search of NCBI db single nucleotide polymorphisms (SNPs) build 127 for SNPs of the 
AGTR1 gene validated by both frequency and cluster data yielded 278 entries with 15 being 
insertion/deletion polymorphisms and 262 SNPs. Located 213–214 base pairs upstream from 
exon 1 are two adjacent SNPs listed in dbSNP as a single insertion/deletion polymorphism 
(rs422858).9 Review of dbSNP submissions and population data demonstrate them to be 
SNPs in linkage disequilibrium (LD) as no evidence of a deletion could be found. For this 
polymorphism, we refer to the major allele as AG and the minor allele as CC. Four SNPs lie 
within the coding region, two of which are synonymous (rs5182 and rs5183) and two 
nonsynonymous polymorphisms. One nonsynonymous SNP (rs12721226) results in a 
change from alanine to threonine at amino acid position 163 and another (rs12721225) a 
change from alanine to serine at amino acid position 244. The one polymorphism not 
documented in dbSNP is a CA dinucleotide repeat microsatellite polymorphism located in 
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the 3′UTR, which has a polymerase chain reaction product ranging between 128 and 146 
basepairs.12,13
Online-only Tables 1A and 1B display allele and genotype frequencies of polymorphisms 
genotyped in populations of at least 100 apparently healthy, unrelated individuals from 
similar ancestry. For inclusion, studies had to be published in the English language and 
genotype distribution in Hardy-Weinburg Equilibrium. Several studies refer to the same 
polymorphism by different names depending on the method of nomenclature, reference 
sequence, and choice of initiation site. Hence, for the purpose of clarity polymorphisms will 
be referred to by their rs numbers. As recommended by the Human Genome Variation 
Society the precise location of each SNP is listed according to the reference genomic 
sequence (AF24599), and that referenced by the literature.14
The most well-studied AGTR1 SNP is rs5186 (also termed the A1166C variant) located in 
the 3′ UTR. Although this SNP does not lie within a coding region or splice site, it has been 
hypothesized that it may affect mRNA stability and transcription, or alternatively be in LD 
with another polymorphism of regulatory significance. Frequencies of this variant range 
from 0.19–0.31 in populations of European descent,15–22 0.03–0.11 in populations of Asian 
descent,23–27 and 0.05–0.08 in studies of populations of African descent.28–33
Data on the function of AGTR1 polymorphisms is limited. One study utilized computational 
software to identify variations that have the potential to create and destroy transcription 
factor binding sites.34 The rs275652 SNP and the rs422858 polymorphisms may have such 
an effect; however, these need to be tested experimentally. Functional analysis of three 
nonsynonymous mutants have demonstrated altered binding affinities, cell surface 
expression and response to angiotensin II.35 Still, these mutants have yet to be confirmed by 
cluster or frequency data as they were induced experimentally. A haplotype within the 
promoter region, T(rs275651) T(rs275652) AG(rs422858) A(rs275653), may have increased 
promoter activity in adrenal cortical and vascular smooth muscle cells.36 It was proposed 
that this may be due to an increased binding of transcription factor C/EBP to the 
oligonucleotide containing the A(rs275653) variant. These data were presented in abstract 
form and complete publication including methods is awaited.
In vitro experiments of AUF1, an mRNA-binding protein, did not reveal any differences in 
binding capacity to the 3′ UTR between the A and C alleles of the rs5186 polymorphism.37 
Some have found an increase in mRNA levels associated with the C allele of rs5186.38 On 
the contrary, Abdollahi et al.39 found rs5186 AGTR1 mRNA levels to be 0.8-fold lower in 
heterozygotes than major allele homozygotes, and 0.27-fold lower in minor allele 
homozygotes. Platelet AGTR1 binding sites do not vary by rs5186 genotype.40
Haplotypes
Data from the International HapMap Project reveal three recombination hotspots within the 
AGTR1 gene.41 Caucasian populations yield two haplotype blocks; combined Japanese and 
Chinese populations three blocks; and African populations four haplotype blocks. Block one 
is the largest, spanning 16 kb and encompassing exon 2 and flanking intronic sequences.41 
Block two is restricted to intron 2 as is the third block for African populations. Haplotype 
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block three in Asian populations encompasses exon 3 and flanking intronic sequences. 
African populations possess a fourth haplotype block that is isolated to intron 3.
Antonellis et al.6 established a SNP map of the AGTR1 gene using a new protocol of long-
range PCR and fragment cloning. 6 LD was greatest within 30kb and D′ was at least 0.70 
within 10 kb.6 Polymorphisms within the promoter region have exhibited extensive LD as 
have SNPs in exon five.39, 42–44 Additionally, LD has been demonstrated between rs5186 
and SNPs within the coding region.39 Haplotype frequencies of the AGTR1 gene in 
populations >100 individuals of similar ancestry are illustrated in Table 1. For inclusion, 
variants had to be found within dbSNP build 127.
Hypertension
According to the WHO, the current definition of hypertension is the persistent elevation of 
blood pressure above 140/90, while at rest, documented on at least three separate 
occasions. 45 In diabetics, blood pressure above 130/80 is defined as pathologic.45 There are 
multiple secondary causes of hypertension, including hyperaldosteronism, Cushing disease, 
and renal artery stenosis.46 Essential hypertension (EH) is diagnosed when there is no 
obvious etiology. It is a complex, multifactorial polygenic disease, and is likely not one 
disease unto itself. Physiologic processes that contribute to the development of hypertension 
and may account for phenotypic variation include salt sensitivity, arterial compliance, 
vasoreactivity, and activity of the renin-angiotensin and adrenergic systems.
Hypertension is extremely common, occurring in 24% of all Americans and 28% in the 
African American population.47 It was estimated in the year 2000 that more than one billion 
people have hypertension and this number may increase by an additional 4% by the year 
2025.48 The highest prevalence of hypertension is in established market economies, former 
socialist economies, and Latin American and Caribbean nations. 48 Estimates in these 
regions range between 35 and 41% in men and 37–39% in women. The lowest prevalence of 
hypertension is in India and southeastern Pacific regions including Korea, Thailand, and 
Taiwan.48 These estimates are as low as 17–21% in men and 14–21% in women. In all 
regions, hypertension prevalence increases with age. Systolic blood pressure levels are 
higher, and hypertension more prevalent in men than women in younger age groups, whereas 
the reverse tends to be true in higher age groups across populations, suggesting a likely 
interaction between these two factors.48, 49 Hypertension is an insidious disease, rarely 
resulting in acute symptoms. When left uncontrolled, however, it can lead to a multitude of 
CVD such as ischemic heart disease (IHD), stroke, congestive heart failure (CHF), and 
kidney disease. There is a log-linear relationship between blood pressure and relative risk of 
cardiovascular endpoints.50 Worldwide, it is estimated that 49% of ischemic heart disease, 
62% of stroke, 76% of a composite outcome of EH, congestive heart failure, and kidney 
disease and 14% of other CVD (retinopathy, peripheral vascular disease) are attributable to a 
mean systolic blood pressure (SBP) >115 mm Hg.51 In the year 2000, approximately 12.8% 
of all deaths (7.1 million) and 4.4% of all disability adjusted life-years (64.3 million) were 
due to suboptimally controlled blood pressure.51 In the United States, it is estimated that as 
many as 50% of hypertensives are uncontrolled even when under the care of a physician.45 
In some populations, especially African Americans, hypertension is difficult to control even 
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with multiple antihypertensive medicines.52 Blood pressure levels and estimates of 
hypertension prevalence are highly variable even within regions of similar ethnic 
ancestry.48,49 Historically, studies within the United States documented higher rates of 
hypertension in individuals of African descent than European descent, suggesting a genetic 
predisposition to hypertension.47 Recent data, however, demonstrate similar hypertension 
prevalence between African Americans and Caucasian individuals residing in European 
nations.53 It has been suggested that environmental factors play at least as great a role in 
blood pressure variation as does genetics.49
Obesity, insulin resistance/diabetes and obstructive sleep apnea are tightly intertwined; 
however, each poses an independent risk factor for hypertension.54–56 Obesity results in 
impaired natriuresis and glomerular hyperfiltration and resultant renal injury which then 
exacerbates sodium retention.54 Obstructive sleep apnea has been found to have similar 
physiologic effects.57 Both obesity and insulin resistance lead to endothelial dysfunction via 
shared and unshared pathways that impact hormone, cytokine, and redox balance.58 
Hyperglycemia in addition to insulin resistance promotes vascular changes and resultant 
hypertension via formation of advanced glycation end products, increased reactive oxygen 
species, and altered growth factor and cytokine production.59
The effect of salt intake on blood pressure variation across populations is well 
established.60,61 An increase of 100mmol/day of salt intake has been estimated to account 
for a 3–6 mm Hg increase in systolic pressure and a 0–3 mm Hg increase in diastolic blood 
pressure.62 Epidemiologic data suggest that at least in some populations, individuals with 
active lifestyles are less prone to hypertension.63,64 Alcohol is also associated with 
hypertension, and the previous notion that moderate alcohol intake or specific forms of 
alcohol was cardioprotective has been dismissed.65 The negative effect of alcohol intake on 
blood pressure is dose-linear and seems to have a greater effect in men than women.66 Even 
when environmental factors are optimized, many continue to manifest with elevated blood 
pressures as a result of genetic predisposition. Hypertension has long been noted to exhibit 
familial clustering, with heritability estimates ranging between 30 and 50%.67–70 The 
genetic basis of hypertension and current methodologic/epidemiologic roadblocks to its 
unraveling has been extensively reviewed.71,72 Both linkage and association studies of 
hypertension-related phenotypes have largely been disappointing with discrepant results due 
to a combination of insufficient power, poor phenotyping, population stratification, epistasis, 
and insufficient attention to gene-environment interactions.71
Genome-wide linkage studies have yielded largely divergent results with the exception of a 
quantitative trait locus for hypertension and/or blood pressure on 2p.73–76 Evidence does 
exist in support of an association between the endothelial nitric oxide synthase gene3 27 
base-pair variable number tandem repeat polymorphism in intron 4 (4a/b) and hypertension 
under a recessive model in Caucasian and Asian populations.77 Notably, findings were 
homogeneous even between studies of different ethnicity. Because of the major role of the 
RAS on blood pressure control, many of its components have been extensively studied with 
regard to hypertension. Results have been largely discrepant with respect to the 
angiotensionogen M235T, 78, 79 angiotensin converting enzyme (ACE) insertion/ deletion, 79 
and aldosterone synthase (CYP11B2) C-344T polymorphisms.80
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Numerous studies have been published associating polymorphisms of AGTR1 with 
hypertension, however results have been inconsistent. The purpose of this review is (1) to 
systematically present data relating AGTR1 gene polymorphisms in association with 
hypertension; and (2) to perform a meta-analysis of association studies of the rs5186 SNP 
and hypertension to both understand the relationship between this genetic variant and 
hypertension across multiple populations, and the apparent heterogeneity of findings 
inherent in the current literature.
METHODS
We searched PubMed (The National Library of Medicine) using the search terms “AGTR1 
polymorphism” including dates 1966–March 2007. Additionally, the bibliographies of 
retrieved articles were reviewed for additional papers. Abstracts from the annual meetings of 
the American Heart Association and American Society of Hypertension were also searched 
for the years 1994–2006. The ISI Web of Science database was also searched for abstracts 
using the terms “AGTR1 Polymorphism Hypertension.” Inclusion criteria were: publication 
in the English language, either a case-control or case cohort study design, outcome of EH 
only, allele and/or genotype frequencies reported, stratification by ethnic background when 
more than one ethnic group was included and study participants at least 18 years of age (as 
the etiology of hypertension in children may be distinct from that in adults). Minor allele 
frequencies and genotype distributions were extracted from publications which focused on 
haplotype analysis, when possible. We additionally attempted to obtain genotype 
distributions of hypertensive and control groups in publications that restricted their analysis 
to minor allele frequencies.
For the rs5186 meta-analysis, the Stata Version 9.0 (Stata-Corp: College Station, TX) user-
written program METAN (Bradburn, Deeks, and Altman) was used for analysis. We began 
by assessing whether there was heterogeneity within populations of similar ancestral 
descent. Some populations were difficult to classify, and hence were placed a priori into the 
population with the closest minor allele frequency. The DerSimonian and Laird random-
effects model was employed to assess heterogeneity.81 The cut point for the χ2 test of 
heterogeneity from the Mantel-Haenszel model was set at P<0.10; this value was chosen 
because tests of heterogeneity are often underpowered. 82 We further assessed heterogeneity 
using the χ2 statistic (the variance between studies) and the τ2 statistic (the proportion of 
total variance that is between studies); we interpreted at least 33% variance between studies 
as indicative of heterogeneity, precluding pooling of summary estimates across studies.83 
Because there were only two studies of populations of African ancestry, we did not assess 
heterogeneity within this stratum.
Heterogeneity between studies may be due to variability in study design characteristics or 
populations of study. For example, studies with older populations may show weaker 
associations between genotype and hypertension because competing risk factors 
predominate in older adults. Therefore, we undertook a meta-regression of available and 
relevant study features including: hypertension definition (“SBP ≥ 160 mm Hg and/or on 
medication” vs. “SBP ≥ 140mmHg and no mention of medication”), mean age of cases, % 
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male composition of cases, total cholesterol levels, and body mass index (BMI). Because of 
the limited number of studies conducted within Asian and African populations, meta-
regression was conducted only within the European ancestry population. For predictors 
significant within the meta-regression (P < 0.10, due to poor power using a small number of 
studies), stratified meta-analysis was performed with testing of between-study heterogeneity 
within each stratum.84 Additionally, multiple publications reported gender-specific data, and 
hence we ran stratified meta-analyses for these studies.
Because multiple and varying models of genetic effects for the hypertension phenotype have 
been assessed in the literature, we calculated odds ratios using multiple genetic models. For 
all polymorphisms the minor allele (a) versus the major allele (A), is considered the risk 
marker for hypertension. First, we calculated pairwise contrasts of the aa versus AA 
genotype and the Aa versus AA genotype (2 df tests). Next, we employed an additive model, 
which assumes a monotonic increase in association with hypertension as one moves from 
zero to one and one to two copies of the minor allele. Finally, we calculated associations 
under an autosomal-dominant model (AD) that combines the aa and Aa genotypes in the 
numerator; and an autosomal-recessive model (AR) that combines the Aa and AA genotypes 
in the denominator. We attempted to infer the most likely model of inheritance by regressing 
the log-odds- ratio of hypertension of the homozygous aa-versus-AA contrast (x-axis) 
against the heterozygous Aa-versus-AA contrast (y-axis), using results of each study. The 
slope of the regression parameter (λ) will be zero under a perfectly AR model (only the aa 
genotype is associated with disease), one under a perfectly AD model (either one or two 
copies of the a allele confers risk of disease), and 0.5 under a codominant model.85
Publication bias was assessed using Begg rank correlation test, Egger weighted regression 
test, and visual inspection of funnel plots of standard error of the log-odds-ratio against the 
log-odds-ratio. Egger test is considered the most sensitive of these tests, although funnel 
plots may reveal publication bias not detected by underpowered formal statistical tests.86
RESULTS
Hypertension
There were 38 studies (one studied two distinct populations) which satisfied inclusion 
criteria and analyzed the rs5186 AGTR1 polymorphism (Table 2) and eight which analyzed 
other SNPs in relation to hypertension categorized as a dichotomous variable (Table 2). Two 
studies were excluded due to analysis of redundant populations,87, 88 one that did not 
genotype its own controls,89 and one because it did not clarify genotype categorization.90 
Two studies analyzed haplotypes of the AGTR1 gene, and risks for individual SNPs could 
not be extracted so these findings will be reported separately. 36, 91
Multiple methodological weaknesses were noted in the majority of studies listed in Tables 4 
and 5. Sample sizes were small, definitions of hypertension were inconsistent between 
studies and sometimes inconsistent with currently accepted guidelines, classification of 
hypertension was based on a single point estimate, and often controls were sampled from 
different populations than cases. There was substantial variability in age, gender 
composition, cholesterol levels, and BMI both within and between studies.
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Forest plots for association studies of rs5186 and hypertension status under dominant, 
recessive and additive genetic models are shown in Figure 1. Table 3 reports the tests of 
heterogeneity (χ2, τ2, and I2), Egger publication bias test, and where appropriate, summary 
estimates (odds ratio (OR) and 95% confidence interval (CI)) of association studies of 
hypertension and rs5186 genotype under each genetic model. The heterogeneity χ2 and I2 
tests led to identical conclusions. Pooled summary estimates are reported when studies may 
be regarded as nonheterogeneous (P<0.10 for the heterogeneity χ2 test, or I2 < 0.33). There 
was significant heterogeneity for both Asian and European populations under most genetic 
models. In searching for the most appropriate genetic model, results were difficult to 
interpret as we obtained slope values >1.0 for European populations and less than zero for 
Asian populations. These results may be related to the observed heterogeneity of studies.
None of the factors we examined explained the heterogeneity for the AR model using meta-
regression. Under the AD model, the definition of hypertension and percent male 
composition of cases were significant predictors of heterogeneity (P < 0.10). For the studies 
that used “SBP ≥160 mm Hg and/or on medication,” odds ratios were 36% greater than 
studies with a definition of “SBP ≥ 140 mm Hg and no mention of medication” (OR 1.36, 
95% CI 1.07–1.74). For the studies that were predominantly male, odds ratios were 60% 
lower than studies that were predominantly female (OR 0.40, 95% CI 0.20–0.82). Next, we 
repeated the meta-analysis within strata identified by the meta-regression results. Strata 
were: definition of hypertension “ 160 mm Hg and/or on medication” versus “ 140 mmHg 
and no mention of medication” and male gender composition of cases ≥ or <50% male. 
Results are given in Table 4. There was no evidence of heterogeneity within studies stratified 
by these variables (P > 0.10). The test of heterogeneity is least powerful when looking 
within strata, and given there were as few as five studies within any stratum these results 
should be interpreted cautiously. Association of rs5186 genotype and hypertension was 
found using an AD model within studies that used a definition of hypertension ≥160 mm Hg 
and/or on medication (D + L pooled OR 1.23, 95% CI 1.06–1.43) and studies that were 
predominantly female (D + L pooled OR 1.28, 95% CI 1.10–1.48). Publication bias was 
evident in both strata (Egger P < 0.001 and P=0.003, respectively). In assessing the most 
appropriate genetic model for analysis, results were difficult to interpret with a slope of >2.0 
in the stratum using a definition of hypertension ≥160 mm Hg and/or on medication and no 
correlation between the aa-versus-AA and Aa versus-AA contrasts in all other strata.
Study-level odds ratios for association of SNPs other than rs5186 with hypertension under 
AD, AR, and additive genetic models are provided in Table 4. Heterogeneity was assessed 
for SNPs with at least three studies including rs1492078 and rs188018 with P-values of < 
0.10 for all genetic models involving rs1492078 and the AR model for rs188018. Results 
were nonheterogeneous for the AD model of rs188018 (P=0.76), although there were a 
limited number of studies. The D + L pooled OR was 0.91 (95% CI 0.72–1.14), showing no 
association with hypertension. It should be noted that results for multiple SNPs were 
identical, given the presence of strong LD.
The AC repeat within the 3′UTR was analyzed in two studies. One found an increased risk 
with the 140 bp fragment in comparison with any other allele (OR 3.21, 95% CI 1.28–
8.04).13 The other examined allele frequencies between the case and control groups and 
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found no difference, and did not report genotype frequencies to allow for additional 
analyses.92
Zhu et al.91 demonstrated a haplotype block containing the C allele from rs5182 and the G 
allele from rs5183 was possibly associated with hypertension in a case-control analysis of 
African Americans (P<0.05). In this same study, using a haplotype transmission 
disequilibrium test in African American families, the CG haplotype was overtransmitted to 
hypertensive offspring (P =0.0002). No association was found in Caucasian Americans in 
this study.91 Another study reported association of a haplotype block within the promoter 
region consisting of: T(rs275651) T(rs275652) AG(rs422858) A(rs275653), to be associated 
with hypertension but only inwomen.36 This haplotype reportedly also has functional 
significance as discussed earlier. Finally, although Gu et al.93 did not report genotype 
frequencies, it is worth mentioning due to its innovative approach which incorporated both 
additive and up to a four-way interactive effect. There were 503 stage two hypertensives and 
490 age/gender-matched controls genotyped for 33 SNPs located in 11 genes 
physiologically relevant to hypertension. AGTR1 SNPs rs275650, rs1492078, and rs5186 
were not found to predict hypertension in a single locus analysis.
Interactions
Epistasis—Interaction between AGT M235T and AGTR1 rs5186 on both hypertension 
and blood pressure was investigated but no effect was demonstrated.92,94,95 In studying 
interaction of the AGTR1 rs5186 with the angiotensin converting enzyme I/D polymorphism 
and hypertension, Ashavaid et al.97 found the C allele to be more frequent in hypertensive 
individuals with the DD genotype. Others have found no interaction between these two 
polymorphisms with regard to hypertension or the normal variation of blood pressure.96–98 
These studies were all underpowered to investigate interaction.
One analysis examined gene-gene interaction between rs275650, rs1492078, and rs5186 
with polymorphisms from 11 other candidate genes on hypertension. There was epistasis 
between the CYP11B2 conversion polymorphism and AGTR1 rs275650 with an OR of 2.10 
(95% CI 1.26–3.51) for A allele homozygotes versus T allele carriers.93
Age of onset of hypertension—Interaction with age of onset of hypertension and 
rs5186 genotype was examined in one small study, which reported null results.99
Diabetes—Interaction between the AGTR1 rs5186 genotype and diabetes was explored in 
a stratified analysis of individuals with diabetes versus those with a normal glucose tolerance 
test.100 No associations were noted.
Cholesterol—One paper investigated the interaction between the AGTR1 rs5186 
polymorphism and cholesterol level on the pathogenesis of hypertension.101 Given that 
cholesterol levels varied between groups in much of the literature, this possibility is 
intriguing. Among those with total cholesterol levels >220 mg/dL, there was a dramatic 
increase in theORfrom1.6 (0.9–3.0) to 6.7 (1.8–24.7). Although CIs are wide, and other 
confounders such as BMI, triglyceride levels, and fasting serum glucose were not accounted 
for, the evidence for biologic plausibility of this interaction is strong. In vitro studies have 
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shown that low density lipoprotein (LDL) upregulates AGTR1 expression.102 Other 
evidence exists that the vascular response to angiotensin II is modified by LDL levels.103
Gender—As mentioned above, the effect of AGTR1 variants on hypertension risk may 
vary by gender. In fact, the response to angiotensin II may be altered by gender104 via 
regulation of the AGTR1.105 One article that examined the effect of gender on blood 
pressure as a continuous variable, did find a numeric increase in systolic and diastolic blood 
pressures in males but not females with the C allele.104
Odds ratios for hypertension in association with rs5186, stratified by gender, are presented in 
Table 4. Under the AD and additive models, Asian male and female strata demonstrated 
significant heterogeneity; however, we were able to pool results for the Asian AR models. 
Results for European populations were nonheterogeneous and summary results are 
displayed. As illustrated in the figures, results are imprecise, but there is suggestion of an 
increased risk that is specific to European females.
DISCUSSION
In summary, the literature regarding the AGTR1 rs5186 polymorphismis heterogeneous, and 
hence use of an overall summary estimate is inappropriate. Variation among studies with 
regard to the definition of hypertension and gender composition helps explain the 
heterogeneity of findings, and the role of these covariates should be explored further. The 
variability between studies with regard to age, cholesterol levels, and BMI also could explain 
the heterogeneity of the prevalent literature given their biologic plausibility. Although we 
didn’t find evidence of their influence on heterogeneity, meta regression with this relatively 
limited number of studies is lacking in power.
Gender-stratified analyses merely suggest that the rs5186 C allele may pose an increased 
risk for hypertension in Caucasian women, as the presence of publication bias is concerning 
and the results were not statistically significant. Nonetheless, supportive of our findings is 
the report of interaction between rs5186 genotype and gender on the renal hemodynamic 
response to angiotensin II.104 Further testing with larger studies or meta-analysis using 
patient-level data are necessary before forming any definitive conclusions.
We must mention two limitations inherent in conducting numerous subgroup analyses, 
including 30 homogeneity χ2 P-value tests and the estimation of 12 CIs (Table 4). First, the 
application of the homogeneity χ2 test to many subgroups (and using a P-value cut point of 
0.10) will sometimes lead to rejection of the null hypothesis by chance alone, and analysts 
generally prefer to be conservative in rejecting the null. Here, the null hypothesis is 
homogeneity, and the alternative hypothesis is heterogeneity. In the context of deciding 
whether or not to pool study results, the multiple-testing approach should err on the side of 
being too conservative (i.e., not pooling results when they should be pooled). Our choice of 
whether to pool or not was supported by the I2 statistic, which was even more conservative 
than the homogeneity P-value in rejecting pooling. We therefore do not feel multiple testing 
for homogeneity is problematic. A second, more vexing problem is that two CIs lie above 
the null value (Table 4), which could have been due to chance. We caution against using the 
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CI as a test of statistical significance, noting that these subgroups show relatively precise 
estimates, and precision is a more robust standard of judging estimates than hypothesis 
testing.106 In judging the validity of the subgroup analyses, other considerations must be 
incorporated (including biological plausibility), and the evidence is weak in this regard.
Another explanation for the inconsistency in results is that binary phenotypes are 
underpowered. It might be that study of blood pressure as a continuous variable would yield 
more consistent findings. The few studies conducted thus far, have found no association 
between rs5186 genotype and blood pressure variation whether studied in population-based 
cohorts, 107–109 hypertensives off antihypertensive medication, 110–112 or nonhypertensive 
populations.94, 95, 98, 113, 114 The lack of a functional role of the rs5186 polymorphism 
makes this SNP somewhat unappealing as a “true” influence of hypertension susceptibility. 
The available evidence for functionality of AGTR1 polymorphisms is mostly confined to 
those within the promoter region. Thus far, studies of promoter region polymorphisms have 
yielded encouraging results especially given many of these SNPs are in LD with one 
another. Given the dedication of the AGTR1 gene to the promoter region and the role of 
splicing variants, this region warrants further investigation. Identification of genetic 
susceptibilities to hypertension has important public health implications given its high 
prevalence and large impact on cardiovascular morbidity and mortality. It is premature to 
conclude any relationship between AGTR1 polymorphic variants and hypertension, and 
hence there is no role for genetic screening at this time. The a priori probability for an 
influential role of the AGTR1 gene on hypertension is quite strong given its biologic 
relevance. Many physiologic mechanisms contribute to hypertension such as activity of the 
noradrenergic and RASs, arterial stiffness, and salt sensitivity. It may be that hypertension 
represents multiple diseases with distinct etiologies. Investigation of these processes as a 
function of genotypic variation might yield more consistent results, as population 
stratification could be minimized.
A handful of studies of the rs5186 SNP in association with hypertension-related physiologic 
mechanisms have been conducted thus far. Studies of the sympathetic postural 
response114, 115 and vascular reactivity to alpha-adrenergic stimulation116–118 have been 
conflicting. Similarly, there have been a variety of contradictory findings in the blood 
pressure109, 119–123 and renal response109, 120, 121 to angiotensin II. There is no variation in 
the aldosterone response to angiotensin II with relation to rs5186 or rs188018 
genotypes.109, 119–121,124 Neither salt sensitivity125, 126 nor renal sodium handling, 127 
seems to vary according to rs5186 genotype. Studies of arterial stiffness as indicated by 
pulse wave velocity110, 128 or pulse pressure129 have been conflicting.
Further study of gene-environment interactions are indicated, particularly with powerful 
population determinants of hypertension such as obesity and salt intake. Study of single 
SNPs in isolation is likely to be fruitless given the complexity of the hypertensive phenotype 
and the need to incorporate multiple variants from multiple genes. Haplotype analysis helps 
to alleviate some of the burden of genotyping and should likely be the rule for future 
association studies rather than the exception. Larger studies with a robust definition of 
hypertension, investigation of processes physiologically relevant to hypertension, 
appropriate sampling of controls, and consideration of epistasis and gene-environment 
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interaction are necessary to make a true determination of whether AGTR1 polymorphisms 
have a role in the pathogenesis of hypertension.
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A C, Forest plots for dominant, recessive, and additive genetic models of rs5186 
polymorphism in association with hypertension, including all studies. (Dotted line represents 
null value.) Filled OR is the adjusted estimate using meta-bias to estimate results if 
publication bias were not present. (1A) Dominant Model: *heterogeneity χ2 P = 0.08; τ2 = 
0.021; I2 = 34%; Egger’s publication bias P = 0.51.†Heterogeneity χ2 P = 0.09; τ2 = 
0.028;I2 = 35%; Egger’s publication bias P = 0.75. (1B) Recessive Model:*heterogeneity χ2 
P = 0.08; τ2 0.074; I2 = 34%; Egger’s publication bias P = 0.98.†Heterogeneity χ2 P = 0.68; 
τ2 = 0.000;I2 = 0%; Egger’s publication bias P = 0.09; Asian summary OR: 0.99 (95%CI: 
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0.59, 1.68). (1C) Additive Model: *heterogeneity χ2 P = 0.001; τ2 = 0.040;I2 =58%; Egger’s 
publication bias P = 0.47. †Heterogeneity χ2 P = 0.15; τ2 = 0.020;I2 =28%; Egger’s 
publication bias P = 0.93; Asian summary OR: 1.07 (0.93, 1.23).
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Table 1
Allele frequencies for CA repeat polymorphism within the 3′ UTR of the AGTR1 gene between positions 
60117 and 60256 of genomic reference sequence AF24599
Base pairs of allele
Allele frequencies
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